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Abstract
Background
Knowledge about the impact of Low-Molecular-Weight Heparin (LMWH) on the coagulation
system in patients undergoing minimal invasive lung cancer surgery is sparse. The aim of
this study was to assess the effect of LMWH on the coagulation system in patients undergo-
ing Video-Assisted Thoracoscopic Surgery (VATS) lobectomy for primary lung cancer.
Methods
Sixty-three patients diagnosed with primary lung cancer undergoing VATS lobectomy were
randomized to either subcutaneous injection with dalteparin (Fragmin®) 5000 IE once daily
or no intervention. Coagulation was assessed pre-, peri-, and the first two days postopera-
tively by standard coagulation blood test, thromboelastometry (ROTEM®) and thrombin
generation.
Results
Patients undergoing potential curative surgery for lung cancer were not hypercoagulable
preoperatively. There was no statistically significant difference in the majority of the
assessed coagulation parameters after LMWH, except that the no intervention group had a
higher peak thrombin and a shorter INTEM clotting time on the first postoperative day and a
lower fibrinogen level on the second postoperative day. A lower level of fibrin d-dimer in the
LMWH group was found on the 1. and 2.postoperative day, although not statistical signifi-
cant. No differences were found between the two groups in the amount of bleeding or num-
ber of thromboembolic events.
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Conclusions
Use of LMWH administered once daily as thromboprophylaxis did not alter the coagulation
profile per se. As the present study primarily evaluated biochemical endpoints, further stud-
ies using clinical endpoints are needed in regards of an optimized thromboprophylaxis
approach.
Introduction
Cancer is generally associated with hypercoagulability [1] and thereby an increased risk of
venous thromboembolic events (VTE). The risk of VTE may be due to increased activation of
the coagulation system, which brings the patient into a hypercoagulable state [2].
The overall evidence for using low-molecular-weight heparin (LMWH) in surgical cancer
patients is relatively weak; only one randomized, controlled trial has been published since
1996, where patients undergoing colorectal surgery either received LMWH or placebo/no
intervention [3]. The authors found no difference between the two regimes. Yet, there are
many observational studies published favouring thromboprophylaxis in cancer patients under-
going surgery, and LMWH is generally recommended [3]. However, the use of LMWH results
in increased cost, an increased risk of bleeding, logistical difficulties, and pain due to the
injection.
LMWH thromboprophylaxis is also widely recommended for patients undergoing lung
cancer surgery [4, 3]. However, only a very limited number of studies have investigated
LMWH’s impact on the coagulation system in lung cancer surgery, and no studies have inves-
tigated it in minimal invasive surgery.
Attaran et al [5] used thromboelastography (TEG1) and found that lung cancer patients
undergoing surgery were not hypercoagulable compared with patients undergoing operation
for benign diseases. They showed that LMWH administration once or twice daily did not pro-
vide sufficient thromboprophylaxis and advocated for screening of patients using TEG1 and
ensuring adequate thromboprophylaxis in hypercoagulable patients only.
Thromboelastometry (ROTEM1), thrombin generation and standard coagulation parame-
ters assess altogether the total haemostatic capacity quantifying both global and dynamic coag-
ulation parameters [6, 7].
It seems important to assemble further knowledge in order to target and optimize the
thromboprophylaxis given, e.g. in terms of type of medication, screening for hypercoagulation,
influence of using a minimal invasive surgical approach, timing and length of prophylaxis.
We hypothesized that LMWH administered once daily would reduce the ROTEM, EXTEM
clotting time following surgery in patients undergoing Video-Assisted Thoracoscopic Surgery
(VATS) lobectomy for primary lung cancer.
Thus, the aim of this study was therefore to assess the effect of LMWH on the coagulation
system in patients undergoing Video-Assisted Thoracoscopic Surgery (VATS) lobectomy for
primary lung cancer.
Materials and methods
Patients referred for lobectomy to Aarhus University Hospital, Rigshospitalet (University Hos-
pital of Copenhagen) or Odense University Hospital, Denmark, in the period from March
2013 to April 2015 was screened for eligibility.
Coagulation profile and lung cancer surgery
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Inclusion criteria were: (1) Diagnosed with primary lung cancer with a preoperative stage
IA-IB; (2) Surgery with expected lobectomy or bi-lobectomy using VATS; (3) Willingness to
participate and ability to give informed oral and written consent; and (4)> 18 years of age at
time of randomization. Exclusion criteria were: (1) Thromboembolic event (either arterial or
venous) within the past three months; (2) Pregnant or lactating; (3) Treatment with vitamin
K-antagonist or a non-vitamin K antagonist oral anticoagulant; or (4) Treatment with a plate-
let inhibitor if this was not paused for a minimum of 5 days (aspirin, clopidogrel or ticagrelor)
or 7 days (prasugrel). No patients had received neoadjuvant chemo- and/or radiation therapy
prior to surgery.
The patients were included after oral and written consent. The protocol for the study com-
plied with the Helsinki II declaration and was approved by the local scientific ethical commit-
tee (File number: 1-10-72-364-12) and The Danish Data Protection Agency. The study was
conducted according to Good Clinical Practice standards and was monitored and approved by
the Good Clinical Practice unit, Aarhus University Hospital, Aarhus, Denmark. The trial was
registered at ClinicalTrials.gov (Identifier: NCT01741506) and at EudraCT no. 2012-002409-
23.
Patients
Sixty-three patients undergoing VATS lobectomy were included. Patients were randomly
assigned to LMWH or no intervention using a computerized prospective randomization
schedule. Randomization was performed in blocks with various sizes in numbers of 2, 4 and 6
without blinding of allocation.
Intervention
Patient randomized to LMWH received dalteparin (Fragmin1) (Pfizer Inc., New York, USA).
It was provided as subcutaneous injections at a dose of 5000 IE once daily, starting the day
before surgery (approximately 12 hours before surgery), and then administered daily at 22:00
(10:00 PM) until the patients were discharged. The patients randomized to no intervention
received no LMWH.
All operations were performed in general anaesthesia with propofol and fentanyl. The
VATS approach used has previously been described in details [8]. Briefly, an anterior approach
with one incision and two port assist incisions were performed, and one chest tube was placed.
All patients were extubated immediately after surgery and mobilized starting on the day of
surgery.
Observation period and blood analyses
Blood samples were obtained and analysed at the following four time-points: 1) Preoperatively;
the day before surgery (and before LMWH potentially were given); 2) Perioperatively at the
time of stapling the bronchus; 3) Postoperatively 08:00 AM at day 1; and 4) Postoperatively
08:00 AM at day 2. LMWH was therefore given approximately 10 hours before blood samples
were taken
The first 2 ml of blood was discarded before drawing blood into tubes containing sodium
citrate for ROTEM1 analyses, thrombin generation and standard coagulation analyses includ-
ing: Activated partial thromboplastin time (APTT), International Normalized Ratio (INR),
fibrinogen (functional, Claus method), fibrin d-dimer, thrombin time, platelet count and fac-
tor (F) VIII:Clot. Blood for ROTEM1 analyses were left at room temperature for 30 minutes
before processing, whereas remaining analyses were done either as routine analyses or blood
samples were centrifuged at 2800 g for 25 minutes and plasma was stored in aliquots at—80˚C.
Coagulation profile and lung cancer surgery
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Regarding thromboelastometry (ROTEM1, Tem International GmbH, Munich, Ger-
many), three standard assays were performed: INTEM, EXTEM, and FIBTEM. We obtained
the dynamic parameters of clot initiation (clotting time: CT, seconds (s)) and clot propagation
(maximum velocity of clot formation: MaxVel, mm x 100/s, time to maximum velocity: tMax-
Vel, s), and whole blood clot strength was assessed by maximum clot firmness (MCF, mm x
100).
Thrombin generation was evaluated by calibrated automated thrombogram (CAT; Throm-
binoscope BV, Maastricht, the Netherlands) using platelet-poor plasma. The following param-
eters were analysed: Lag-time until initial thrombin generation (minutes), maximum
concentration of thrombin (peak, nM), time to peak (ttpeak, minutes), and the endogenous
thrombin potential (ETP, nM x minutes).
Reference values for the ROTEM1 was calculated based on data obtained from 73 healthy
individuals previously published [9], while reference values for thrombin generation was
obtained from 32 individuals published by Collins PW et al. [10].
APTT (Platelin LS, Organon, Munich, Germany), INR (Owren’s PT-reagent, MediRox),
fibrinogen (Clauss method, Siemens Dade reagent), thrombin time (Siemens Test Thrombin),
fibrin d-dimer (Siemens INNOVANCE1 D-Dimer reagent), and Anti-Xa (Berichrom hepa-
rin, Siemens) were analysed employing the CS2100i (Sysmex, Kobe Japan). Factor VIII:Clot
was analysed by ACL-TOP (Istrumental Laboratory, Bedford, MA, USA)
Preoperative data in terms of clinical characteristics was collected systematically from medi-
cal records. Furthermore, peri- and postoperative data (e.g. operating time, bleeding during
surgery, total drain loss, VTE and adverse events) was collected prospectively. VTE were cap-
tured through clinical assessment and by reviewing medical records. If VTE was suspected, an
ultrasound was performed.
All patients were contacted by phone 30 days after the operation and had also their medical
records reviewed.
Statistical analyses, endpoints and sample size
Baseline data, peri- and postoperative characteristics were presented using descriptive statis-
tics. Results of the coagulation analyses were tested for normal distribution and hence pre-
sented as either mean and standard deviation (SD) or median and 95% confidence interval
(CI) or as minimum to maximum values. Normally distributed data was compared using Stu-
dent’s unpaired t-tests, while non-normally distributed data was compared using Mann-Whit-
ney U-tests.
Microsoft1 Excel1 for Mac 2011 (Microsoft1, Seattle, USA) and GraphPad Prism for Mac
(GraphPad Software, Inc., CA, USA) was used for the statistical analyses.
The study was primarily an explorative study, and the sample size is therefore associated
with some uncertainty. We based it on the ROTEM1 EXTEM: CT (clotting time). We were not
able to find any studies investigating ROTEM1 in thoracic surgical patients undergoing opera-
tions for lung cancer. In a healthy population the mean is 60 sec with a SD of 25 sec. [9]. The
minimal relevant difference in terms of clotting was designated to 20 sec. In order to detect this
difference with a type I error of 0.05 and 90% power, 27 patients were needed in each group.
Due to the anticipated missing values, 30 patients in each group were considered appropriate.
Analysis was done using the intention to treat principal.
Results
Fig 1 displays the trial flowchart. A total of 81 VATS-patients were randomized; 40 patients to
the LMWH arm and 41 patients to the no intervention group. In the LMWH arm 8 patients
Coagulation profile and lung cancer surgery
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were excluded due to: lacking > one blood sample (n = 5), received acetylsalicylic acid (ASA)
in terms of aspirin (n = 1), did not receive LMWH (n = 1), non-malignant diagnosis (n = 1). A
total of 32 patients were therefore included in the LMWH arm, of which 2 patients had been
given Non-Steroid Anti Inflammatory Drug (NSAID). Additionally, 1 patient was converted
to an open procedure.
In the no intervention arm, 10 patients were excluded due to: lacking > one blood sample
(n = 2), received ASA (n = 3), received LMWH (n = 1), preoperative N1 disease (n = 1), sar-
coma metastasis (n = 1), non-malignant diagnosis (n = 1) and lack of patient cooperation
Fig 1. Trial flowchart for patients planned for Video-Assisted Thoracoscopic Surgery (VATS) lobectomy for primary lung cancer. *: Estimated
with some uncertainty. 1: This includes: 1) Patients operated on Thursday and Fridays; 2) No specialized laboratory technicians available; 3) Not
practical possible to get permission from the patient to participate; 4) Other logistic problems. Abbreviations: n/N: numbers; ASA: Acetylsalicylic
acid (aspirin); LMWH: Low-Molecular-Weight Heparin; NSAID: Non-Steroid Anti Inflammatory Drug.
doi:10.1371/journal.pone.0171809.g001
Coagulation profile and lung cancer surgery
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(n = 1). A total of 31 patients were therefore included in the no intervention arm, of which 3
had been given NSAID. Additionally, 3 patients were converted to an open procedure. Thus, a
total of 63 patients were included in the analyses.
Table 1 shows baseline/preoperative characteristics. As expected there was no statistically
significant difference due to the randomization (p-values not shown). The peri- and postoper-
ative data are displayed in Table 2. There was no difference in terms of perioperative bleeding
or in the total amount of fluid drained. As expected we found a limited number of major
adverse events (death, major bleeding and thromboembolic events). However, there was a ten-
dency towards more adverse events in the no intervention group (3 in the LMWH group and 5
in the no intervention group). There was one death in LMWH group and two incidents of apo-
plexia cerebri in the no intervention group.
Patients experiencing atrial fibrillation was converted to sinus rhythm using amiodarone,
and no additionally antithrombotic treatment were provided.
The results of the standard coagulation blood tests are shown in Table 3, ROTEM1 results
in Table 4, and thrombin generation in Table 5. Overall, patients did not show a hypercoagula-
ble state prior to surgery. However, 13 patients in the LMWH group had FIBTEM maximum
clot firmness (MCF) above 20 mm compared with 15 patients in the no intervention group.
Table 1. Baseline data (preoperative) from 63 patients planned for Video-Assisted Thoracoscopic
Surgery (VATS) lobectomy for primary lung cancer.
Characteristic LMWH group
(N = 32)
No intervention group
(N = 31)
Age (years) 69.8 (7.3) 67.0 (10.3)
Sex (n female/n male) 15/17 20/11
Non smoker/ex-smoker/ active smoker, n 1/24/7 1/19/11
Pack years of smoking 30.9 (23.3) 29.8 (19.9)
FEV 1 (% of expected) 83.4 (27.0) 91.1 (20.0)
DLCO (% of expected) 69.0 (24.2) 68.8 (16.7)
BMI 25.8 (4.0) 24.7 (3.6)
Co-morbidity1, n:
Diabetes 3 2
Hypertension 13 12
Hyperlipidemia 9 10
Cardial and/or vascular disease 8 4
Previous malignant disease 6 8
ASA prescribed, n (%) 7 (22) 6 (19)
Laboratory analyses reference interval):
B—Haemoglobin (women: 7.3–9.5 mmol/L; men: 8.3–
10.5 mmol/L)
8.6 (0.9) 8.5 (0.7)
B—Leukocytes (3.5–10.0 x109/L) 7.9 (1.9) 7.5 (2.0)
P—Creatinine (45–105 μmol/L) 73 (20) 72 (18)
B—Platelet count (145–400 x109/L) 289 (69) 287 (85)
P—CRP (< 8 mg/L) 7.7 (12.3) 4.0 (4.3)
INR (< 1.2) 1.0 (0.1) 1.0 (0.1)
All values are provided either as mean (standard deviation) or numbers (percentage).
1Defined as the patient being in medical treatment for the disease.
Abbreviations: B: Blood; N/n: Numbers; P: Plasma; ASA: Acetylsalicylic acid (aspirin); BMI: Body Mass
Index; CRP: C-reactive protein; DLCO: Diffusion Capacity of the Lung for Carbon Monoxide; FEV: Forced
Expiratory Volume; INR: International Normalized Ratio; LMWH: Low-Molecular-Weight Heparin.
doi:10.1371/journal.pone.0171809.t001
Coagulation profile and lung cancer surgery
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A lower level of fibrin d-dimer in the LMWH group was found on the 1. and 2.postopera-
tive day, although not statistical significant.
The only statistically significant differences were that the no intervention group had a
shorter INTEM CT on the first postoperative day compared to the LMWH group and a lower
fibrinogen level on the second postoperative day and a higher peak thrombin as well.
The anti-Xa activity was analysed in the blood-samples taken perioperative and on the 1.
postoperative day and 2.postoperative day for the patients randomized to LMWH. The results
are presented in Table 6.
Discussion
In this randomized, controlled trial we found that in patients undergoing VATS lobectomy for
primary lung cancer, the coagulation profile did not differ whether the patients were given
Table 2. Peri- and postoperative data from 63 patients planned for Video-Assisted Thoracoscopic Surgery (VATS) lobectomy for primary lung
cancer.
Characteristic LMWH group (N = 32) No intervention group (N = 31) p-value
Type of lobectomy
Right Upper Lobe 10 10 -
Right Middle Lobe 1 1 -
Right Lower Lobe 8 10 -
Left Upper Lobe 9 7 -
Left Lower Lobe 4 3 -
Operating time (h:mm) 2:29 (0:47) 2.31 (0:47) 0.43
Bleeding/drainage during surgery (mL) 100 (0–300) 100 (0–2000) 0.96
Use of inotropes (n of patients)1 17 15 -
Re-operated (n) 1 1 -
Total amount of fluid in the chest drain (mL) 760 (50–4356) 850 (50–6135) 0.91
Complications2 (n) 23 54 -
VTE events 0 0 -
Death (n) 15 0 -
Total length of stay (days) 6.3 (3.0–32.4) 5.5 (3.2–20.0) 0.31
Type of cancer
Adenocarcinoma 22 23 -
Squamous cell carcinoma 8 4 -
Carcinoid (all types) 0 1 -
Others6 2 3 -
Pathological staging -
Stage IA+B 28 27 -
Stage IIA+B 4 4 -
Microscopically free resection margins (R0) 32 31 -
Values for the operating time are provided as mean (standard deviation) and tested using a t-test. The other values are displayed as median (minimum to
maximum) since data was not normally distributed. Difference was tested using Mann-Whitney U-test.
1Predominantly small doses of methaoxidrin or efedrin.
2Includes myocardial infarction, apoplexia cerebri and atrial fibrillation.
3Both were atrial fibrillation.
4Apoplexia cerebri (n = 2) and atrial fibrillation (n = 3).
5Died postoperatively (probably due to bleeding (tamponade)).
6Includes small cell carcinoma, neuroendocrine and sarcotomoid tumor.
Abbreviations: N/n: Numbers; LMWH: Low-Molecular-Weight Heparin; H: Hours; mL: Milliliter; Mm: Minutes; VTE: Venous Tromboembolic Events.
doi:10.1371/journal.pone.0171809.t002
Coagulation profile and lung cancer surgery
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LMWH or not. The effect of LMWH administered once daily thus seemed limited as estimated
by a wide range of coagulation analyses. To our knowledge, the impact on coagulation of
LMWH given to VATS lobectomy patients has not been investigated before. Furthermore, we
did not find that patients with low-stage lung cancer were hypercoagulable preoperatively.
Due to the large amount of coagulation analyses performed, the risk of committing type I
errors increases. Accordingly, we found no clear pattern in the three analyses that differed sig-
nificantly between the LMWH and the no intervention group. We did not find that patients
undergoing potential curative surgery for lung cancer were hypercoagulable preoperatively,
except for FIBTEM MCF, which was elevated in approximately 45% of patients. This is in
accordance with the findings by Attaran et al [5] and supports the assumption that the effect of
LMWH on the coagulation system is limited. These patients suffer predominantly from early-
stage lung cancer, and are not as likely in a hypercoagulable state as are patients with more
advanced disease [5]. We used the widely applied regimen with dalteparin (Fragmin1) 5000
IE given once daily, and the lack of biochemical effect can probably be ascribed to the fact that
the patients did not become hypercoagulable following surgery.
A lower level of Fibrin d-dimer in LMWH group on was found on the 1.postoperative day
and 2.postoperative day, although not statistical significant. This, however, does not indicate
the absence of an effect, but could because the study was underpowered.
The anti Factor Xa after prophylactic doses of LMWH is normally in the range of 0.2–0.5
IU/ml, which are measured 4 hours after injection [11]. However, blood-samples taken on the
1. and 2. postoperative day were obtained 10 hours after injection, and the preoperative sam-
ples were obtained approximately 12 hours after injection of LMWH. Accordingly, our results
are lower than 0.2–0.5 IU/ml. Yet, the level of anti Factor Xa was elevated, documenting that
the LMWH was administrated.
We did not analyse it in the preoperative blood-sample, since this was taken before the
patients randomized to LMWH would receive LMWH. This analysis is only relevant in the
group randomized to receive low-molecular-weight heparin (LMWH), since analysis of anti-
Xa activity provides no information for patients not receiving LMWH or heparin.
The Prothrombin fragment 1 + 2 (PTF) and thrombin–antithrombin III complex (TAT)
are generally considered as markers of thrombin generation [12].
Different types of coagulation analyses have been used to potentially predict VTE in cancer
patients in several studies. Analyses covers thromboelastography [13], thrombin generation
Table 6. Anti-factor Xa data from 32 patients planned for Video-Assisted Thoracoscopic Surgery
(VATS) lobectomy for primary lung cancer and randomized to receive Low-Molecular-Weight Heparin
(LMWH).
Anti–factor Xa (IU/mL) LMWH group
Perioperative
Median (95% CI) 0.00 (0.01–0.08)
1.postoperative day
Mean (SD) 0.20 (0.14)
2.postoperative day
Mean (SD) 0.15 (0.07)
Anti-factor Xa data are for blood-samples taken perioperative and on the 1. and 2.postoperative day.
Normally distributed data are shown as means (standard deviations), whereas non-normally distributed data
are shown as medians and (95% confidence intervals).
Abbreviations: CI: Confidence intervals; N/n: Numbers; IU: International Unit; LMWH: Low-Molecular-Weight
Heparin; mL: Milliliter; SD: Standard deviation.
doi:10.1371/journal.pone.0171809.t006
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[14], markers of thrombin generation (prothrombin fragment 1 + 2) [15] and standard coagu-
lation parameters [15]. The results of these coagulation analyses correlated with clinical events
such as bleeding and VTE [16]. Attaran et al [5] recommended screening of patients to identify
the patients being hypercoagulable and targeting thromboprophylaxis in this specific patient
group. The question is how and when to perform such a screening; one approach could be to
screen preoperatively using thromboelastography (TEG1 or ROTEM1). Future studies using
clinical endpoints will hopefully clarify the potential value of this approach.
It should be emphasized that thrombin generation parameters obtained by calibrated auto-
mated thromboelastography estimate the thrombin generation potential in the patient, which
not necessarily reflects activity in vivo. In order to reflect in vivo activity in the coagulation sys-
tem and depict whether a patient is actively producing thrombin and/or fibrin, measurement
of prothrombin fragment 1+2 or thrombin-antithrombin (TAT) should be used. In this study
measurement of thrombin generation was used to describe the clotting potential and whether
this was altered by LMWH treatment, and in order to depict active coagulation processes mea-
surement of D-dimer was included.
Since we merely used surrogate endpoints, our study was mainly explorative and was not
powered for detecting statistically differences regarding clinical endpoints. To gain further
knowledge, a large study with clinical endpoints is needed.
However, in patients with low stage lung cancer undergoing VATS lobectomy, LMWH as
prophylaxis administrated pre- and perioperatively had no significant impact on the coagula-
tion system.
However, the potential effect of LMWH in reducing VTE could be a systematic effect and
not reflected by the applied coagulation analysis, but as stated above there is a correlation
between the analysis applied and the incidence of VTE [16].
Thoracic surgical clinical practice has over the recent years changed dramatically with the
increasing use of minimal invasive surgery, which reduces the surgical trauma and hence facil-
itates recovery and mobilisation. We also demonstrated that VATS lobectomy only posed min-
imal impact on the coagulation system, which could be due to the minimal trauma using this
approach [8].
The use of medical prophylaxis implies drawbacks as increased cost, an increased risk of
bleeding, logistical difficulties, and pain due to the injection. However, more important than
these drawbacks is that an optimized and more targeted and specific approach of thrombopro-
phylaxis could be provided in the future. As stated in the introduction the recommendations
regarding the use of LMWH is mostly based on observational studies.
Potentially, LMWH could be started after discharge from the hospital or merely given to
those with a high stage tumour and/or given adjuvant chemotherapy. Alternatively, if other
types of thromboprophylaxis (e.g. non-vitamin K antagonist oral anticoagulants) have a more
profound impact on the coagulation analyses, they could potentially replace LMWH.
The strengths of the present study are the reliable study design in terms of randomization
to different regimens, the multi-centre study design (providing a high external validity) and
the use of advanced and validated coagulation analyses. Our study has of course limitations
since we used surrogate and not clinical endpoints in terms of VTE and bleeding events.
Accordingly, we found no difference in VTE, which our study was not designed or powered to
detect (needs > 2000 patients in each group). From a methodological point of view, the results
are limited by the fact that both ROTEM1 and trombin generation analyses reflect coagulation
potential and not necessarily the in vivo coagulation activity.
On the positive side, we did not find any detrimental impact of LMWH either. We had a
limited follow-up time of 30 days postoperatively. However, we find that this fully reflects the
entire perioperative period. We had a relatively high dropout rate due to the complex set-up
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regarding blood sampling and analyses, and the potential interaction with medication (e.g.
aspirin and NSAID). However, this should not interfere with either the internal and external
validity of our study.
In conclusion, use of LMWH administered once daily as thromboprophylaxis did not alter
the coagulation profile per se. As the present study primarily evaluated biochemical endpoints,
further studies using clinical endpoints are needed in regards of an optimized thromboprophy-
laxis approach.
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